Trial results

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647 on ClinicalTrials.gov · last registry update 2026-08-03

Finished 12 May 2025, after enrolling 120 people. Primary outcome, as filed: Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P4

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

University of Pennsylvania

Sponsor type

Other

Enrollment

120

Started

2022-07-26

Primary completion

2025-05-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.